{
    "nct_id": "NCT01088750",
    "official_title": "First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents",
    "criteria": {
        "raw_text": "Inclusion criteria:\n\n* nodular lymphocyte-predominant Hodgkin's lymphoma confirmed by reference pathology.\n* initial stage IA/IIA (according to local staging) or relapse stage IA or IIA and residual tumour after relapse biopsy and no additional surgery planned in nLP patients relapsing after surgery alone\n* patient aged under 18 years at time of diagnosis\n* written informed consent of the patient and/or the patient's parents or guardian according to national laws\n\nExclusion criteria\n\n* pre-treatment of Hodgkin's lymphoma differing from study protocol\n* Any extra-nodal involvement\n* Inability to fulfil protocol requirements for imaging (CT, MRI, FDG-PET) at staging and response assessment\n* known hypersensitivity or contraindication to study drugs\n* prior chemotherapy or radiotherapy\n* Current or recent therapy (within 30 days prior to the start of trial treatment) with steroids\n* Current or recent (within 30 days prior to the start of trial treatment) treatment with another investigational drug or participation in another investigational trial\n* other (simultaneous) malignancies\n* severe concomitant diseases (e.g. immune deficiency syndrome)\n* known HIV positivity\n* pregnancy and / or lactation\n* females who are sexually active refusing to use effective contraception (oral contraception, intrauterine devices, barrier method of contraception in conjunction with spermicidal jelly or surgical sterile) (except for surgery only)\n\nsex: ALL\n\nmaximumAge: 17 Years\n\nstdAges: ['CHILD']",
        "inclusion": "* nodular lymphocyte-predominant Hodgkin's lymphoma confirmed by reference pathology.\n* initial stage IA/IIA (according to local staging) or relapse stage IA or IIA and residual tumour after relapse biopsy and no additional surgery planned in nLP patients relapsing after surgery alone\n* patient aged under 18 years at time of diagnosis\n* written informed consent of the patient and/or the patient's parents or guardian according to national laws",
        "exclusion": "* pre-treatment of Hodgkin's lymphoma differing from study protocol\n* Any extra-nodal involvement\n* Inability to fulfil protocol requirements for imaging (CT, MRI, FDG-PET) at staging and response assessment\n* known hypersensitivity or contraindication to study drugs\n* prior chemotherapy or radiotherapy\n* Current or recent therapy (within 30 days prior to the start of trial treatment) with steroids\n* Current or recent (within 30 days prior to the start of trial treatment) treatment with another investigational drug or participation in another investigational trial\n* other (simultaneous) malignancies\n* severe concomitant diseases (e.g. immune deficiency syndrome)\n* known HIV positivity\n* pregnancy and / or lactation\n* females who are sexually active refusing to use effective contraception (oral contraception, intrauterine devices, barrier method of contraception in conjunction with spermicidal jelly or surgical sterile) (except for surgery only)"
    }
}